Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()

• This case reports the treatment of neuroendocrine carcinoma of the cervix with a PARPi based on NGS. • NGS reports have demonstrated somatic mutations BRCA in neuroendocrine carcinoma of the cervix. • The use of a PARPi in neuroendocrine carcinoma of the cervix has not been previously reported....

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Peter G., Sierk, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804835/
https://www.ncbi.nlm.nih.gov/pubmed/31649992
http://dx.doi.org/10.1016/j.gore.2019.100499
_version_ 1783461276017491968
author Rose, Peter G.
Sierk, Anne
author_facet Rose, Peter G.
Sierk, Anne
author_sort Rose, Peter G.
collection PubMed
description • This case reports the treatment of neuroendocrine carcinoma of the cervix with a PARPi based on NGS. • NGS reports have demonstrated somatic mutations BRCA in neuroendocrine carcinoma of the cervix. • The use of a PARPi in neuroendocrine carcinoma of the cervix has not been previously reported.
format Online
Article
Text
id pubmed-6804835
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68048352019-10-24 Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing() Rose, Peter G. Sierk, Anne Gynecol Oncol Rep Case Report • This case reports the treatment of neuroendocrine carcinoma of the cervix with a PARPi based on NGS. • NGS reports have demonstrated somatic mutations BRCA in neuroendocrine carcinoma of the cervix. • The use of a PARPi in neuroendocrine carcinoma of the cervix has not been previously reported. Elsevier 2019-09-12 /pmc/articles/PMC6804835/ /pubmed/31649992 http://dx.doi.org/10.1016/j.gore.2019.100499 Text en © 2019 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Rose, Peter G.
Sierk, Anne
Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()
title Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()
title_full Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()
title_fullStr Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()
title_full_unstemmed Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()
title_short Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()
title_sort treatment of neuroendocrine carcinoma of the cervix with a parp inhibitor based on next generation sequencing()
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804835/
https://www.ncbi.nlm.nih.gov/pubmed/31649992
http://dx.doi.org/10.1016/j.gore.2019.100499
work_keys_str_mv AT rosepeterg treatmentofneuroendocrinecarcinomaofthecervixwithaparpinhibitorbasedonnextgenerationsequencing
AT sierkanne treatmentofneuroendocrinecarcinomaofthecervixwithaparpinhibitorbasedonnextgenerationsequencing

Ejemplares similares